Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
28M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
14.4M
-
Shares change
-
-564K
-
Total reported value, excl. options
-
$86.2M
-
Value change
-
-$4.44M
-
Put/Call ratio
-
0.52
-
Number of buys
-
32
-
Number of sells
-
-34
-
Price
-
$6.00
Significant Holders of NextCure, Inc. - Common Stock (NXTC) as of Q4 2021
83 filings reported holding NXTC - NextCure, Inc. - Common Stock as of Q4 2021.
NextCure, Inc. - Common Stock (NXTC) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 14.4M shares
of 28M outstanding shares and own 51.26% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (2.71M shares), Sofinnova Investments, Inc. (2.67M shares), BlackRock Inc. (1.24M shares), MILLENNIUM MANAGEMENT LLC (1.01M shares), Woodline Partners LP (756K shares), VANGUARD GROUP INC (752K shares), FEDERATED HERMES, INC. (526K shares), Lombard Odier Asset Management (Switzerland) SA (407K shares), CITADEL ADVISORS LLC (394K shares), and GOLDMAN SACHS GROUP INC (333K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.